Aclaris Therapeutics, Inc. (ACRS)

NASDAQ: ACRS · Real-Time Price · USD
2.240
-0.070 (-3.03%)
Feb 21, 2025, 4:00 PM EST - Market closed
-3.03%
Market Cap 239.72M
Revenue (ttm) 27.08M
Net Income (ttm) -37.00M
Shares Out 107.02M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 364,940
Open 2.290
Previous Close 2.310
Day's Range 2.220 - 2.335
52-Week Range 0.952 - 5.170
Beta 0.52
Analysts Strong Buy
Price Target 11.00 (+391.07%)
Earnings Date Mar 4, 2025

About ACRS

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials f... [Read more]

Sector Healthcare
IPO Date Oct 7, 2015
Employees 91
Stock Exchange NASDAQ
Ticker Symbol ACRS
Full Company Profile

Financial Performance

In 2023, Aclaris Therapeutics's revenue was $31.25 million, an increase of 5.03% compared to the previous year's $29.75 million. Losses were -$88.48 million, 1.81% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 391.07% from the latest price.

Price Target
$11.0
(391.07% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)...

9 days ago - GlobeNewsWire

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammato...

22 days ago - GlobeNewsWire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candid...

6 weeks ago - GlobeNewsWire

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

HC Wainwright & Co. analyst Raghuram Selvaraju upgraded Aclaris Therapeutics Inc ACRS from Neutral to Buy and a price target of $20. The stock gained after the rerating.

2 months ago - Benzinga

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

3 months ago - GlobeNewsWire

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

On Monday, Aclaris Therapeutics, Inc.  ACRS entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, no...

3 months ago - Benzinga

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics...

3 months ago - PRNewsWire

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

- Enhances Aclaris' pipeline with complementary biologics portfolio - - Expands leadership team with addition of seasoned biotech executives - - Management to host conference call today at 8:30 AM ET ...

3 months ago - GlobeNewsWire

Aclaris Therapeutics Announces $80 Million Private Placement

WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candid...

3 months ago - GlobeNewsWire

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea

5 months ago - GlobeNewsWire

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...

5 months ago - GlobeNewsWire

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris...

7 months ago - GlobeNewsWire

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAn...

8 months ago - GlobeNewsWire

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

9 months ago - GlobeNewsWire

American Clinical Research Services Announces Strategic Acquisition of Elixia

RALEIGH, N.C.--(BUSINESS WIRE)--American Clinical Research Services Announces Strategic Acquisition of Elixia.

10 months ago - Business Wire

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Results Conference Call May 7, 2024 5:00 PM ET Company Participants Kevin Balthaser - Chief Financial Officer Neal Walker - Interim Chief Executive Of...

10 months ago - Seeking Alpha

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a cli...

10 months ago - GlobeNewsWire

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

CAMBRIDGE, Mass. , April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other d...

10 months ago - PRNewsWire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

1 year ago - GlobeNewsWire

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777 Was W...

1 year ago - GlobeNewsWire

Aclaris Therapeutics Provides Corporate Update

- ATI-1777 Phase 2a Trial Results Published in JID Innovations - - ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 - - Aclaris Announces Reduction in Workforce -

1 year ago - GlobeNewsWire

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, ...

1 year ago - GlobeNewsWire

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Aclaris Therapeutics on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial.

1 year ago - Reuters

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Web...

1 year ago - GlobeNewsWire

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

- Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Toplin...

1 year ago - GlobeNewsWire